The CACM experts consensus for expert consensus on the clinical application of Longxin capsule in the treatment of ischemic stroke

Title: The CACM experts consensus for expert consensus on the clinical application of Longxin capsule in the treatment of ischemic stroke
Edition: Original
Classification: Experts consensus
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: Clinicians in hospitals and primary medical and health institutions at all levels across the country (professionals of traditional Chinese medicine, western medicine, and integrated traditional Chinese and western medicine)
Evidence classification method: This consensus adopts the GRADE system, an internationally recognized recommendation standard for grading evidence. The formation of expert consensus opinion adopts the nominal group method, which mainly considers six factors: evidence quality, efficacy, safety, economy, patient acceptability and others.
Development unit: 中国中医科学院西苑医院、广东省中医院、中国中医科学院中医临床基础医学研究所、云南永安制药有限公司
Registration time: 2022-08-02
Registration number: PREPARE-2022CN440
Purpose of the guideline: To further clarify the efficacy of Longxinsu Capsules in the treatment of ischemic stroke, dosing schedule and timing, dosage and course characteristics, safety issues, etc., in order to improve clinical efficacy, promote rational drug use, and reduce drug risks.